These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 10485471

  • 1. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
    Yoshinari T, Ohkubo M, Fukasawa K, Egashira S, Hara Y, Matsumoto M, Nakai K, Arakawa H, Morishima H, Nishimura S.
    Cancer Res; 1999 Sep 01; 59(17):4271-5. PubMed ID: 10485471
    [Abstract] [Full Text] [Related]

  • 2. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
    Yoshinari T, Matsumoto M, Arakawa H, Okada H, Noguchi K, Suda H, Okura A, Nishimura S.
    Cancer Res; 1995 Mar 15; 55(6):1310-5. PubMed ID: 7882328
    [Abstract] [Full Text] [Related]

  • 3. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H, Morita M, Sakaizumi N, Fukasawa K, Yoshida E, Okura A, Yoshinari T, Nishimura S.
    Cancer Res; 1999 Jun 01; 59(11):2701-8. PubMed ID: 10363995
    [Abstract] [Full Text] [Related]

  • 4. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C, Qu X, Chaires JB, Colson P, Houssier C, Ohkubo M, Nishimura S, Yoshinari T.
    J Med Chem; 1999 Jul 29; 42(15):2927-35. PubMed ID: 10425102
    [Abstract] [Full Text] [Related]

  • 5. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, Pommier Y.
    Cancer Res; 2001 Jan 15; 61(2):504-8. PubMed ID: 11212241
    [Abstract] [Full Text] [Related]

  • 6. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
    Bailly C, Dassonneville L, Colson P, Houssier C, Fukasawa K, Nishimura S, Yoshinari T.
    Cancer Res; 1999 Jun 15; 59(12):2853-60. PubMed ID: 10383146
    [Abstract] [Full Text] [Related]

  • 7. DNA binding properties of the indolocarbazole antitumor drug NB-506.
    Carrasco C, Vezin H, Wilson WD, Ren J, Chaires JB, Bailly C.
    Anticancer Drug Des; 2001 Jun 15; 16(2-3):99-107. PubMed ID: 11962518
    [Abstract] [Full Text] [Related]

  • 8. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice.
    Arakawa H, Iguchi T, Morita M, Yoshinari T, Kojiri K, Suda H, Okura A, Nishimura S.
    Cancer Res; 1995 Mar 15; 55(6):1316-20. PubMed ID: 7882329
    [Abstract] [Full Text] [Related]

  • 9. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U, Voigt W, Hilger RA, Yin MB, Harstrick A, Seeber S, Rustum YM.
    Oncol Res; 1997 Mar 15; 9(9):485-94. PubMed ID: 9495454
    [Abstract] [Full Text] [Related]

  • 10. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
    Qu X, Chaires JB, Ohkubo M, Yoshinari T, Nishimura S, Bailly C.
    Anticancer Drug Des; 1999 Oct 15; 14(5):433-42. PubMed ID: 10766298
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.
    Takenaga N, Ishii M, Nakajima S, Hasegawa T, Iwasa R, Ishizaki H, Kamei T.
    Drug Metab Dispos; 1999 Feb 15; 27(2):205-12. PubMed ID: 9929504
    [Abstract] [Full Text] [Related]

  • 13. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110.
    Yoshinari T, Yamada A, Uemura D, Nomura K, Arakawa H, Kojiri K, Yoshida E, Suda H, Okura A.
    Cancer Res; 1993 Feb 01; 53(3):490-4. PubMed ID: 8381047
    [Abstract] [Full Text] [Related]

  • 14. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C, Carrasco C, Hamy F, Vezin H, Prudhomme M, Saleem A, Rubin E.
    Biochemistry; 1999 Jul 06; 38(27):8605-11. PubMed ID: 10393535
    [Abstract] [Full Text] [Related]

  • 15. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y, Weinstein JN, Kohn KW, Shi LM, Pommier Y.
    J Med Chem; 1998 Jun 18; 41(13):2216-26. PubMed ID: 9632354
    [Abstract] [Full Text] [Related]

  • 16. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C, Riou JF, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M.
    Biochemistry; 1997 Apr 01; 36(13):3917-29. PubMed ID: 9092822
    [Abstract] [Full Text] [Related]

  • 17. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
    Takenaga N, Hasegawa T, Ishii M, Ishizaki H, Hata S, Kamei T.
    Drug Metab Dispos; 1999 Feb 01; 27(2):213-20. PubMed ID: 9929505
    [Abstract] [Full Text] [Related]

  • 18. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Antony S, Jayaraman M, Laco G, Kohlhagen G, Kohn KW, Cushman M, Pommier Y.
    Cancer Res; 2003 Nov 01; 63(21):7428-35. PubMed ID: 14612542
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.